The latest biotech news

News and Trends 8 Nov 2022

Vir Biotech presents new data for functional cure of chronic Hep B virus

Vir Biotechnology, Inc. today (November 8) announced new data from its robust hepatitis B virus (HBV) portfolio aimed at achieving a functional cure. These data, plus health outcomes research, are being presented at the American Association for the Study of Liver Diseases (AASLD). The Liver Meeting was delivered in two oral presentations, both of which were selected […]

November 8, 2022 - 3 minutesmins - By Liza Laws

More News! 8 Nov 2022

ISA Pharmaceuticals’ Amplivant adjuvant boosts immune response in SLP immunotherapy

ISA Pharmaceuticals B.V, a Netherlands-based clinical stage biotech developing immunotherapies to treat cancers and infectious diseases has had a phase 1 clinical study published. The study, using ISA Pharmaceuticals’ Amplivant adjuvant and synthetic long peptide (SLP) therapeutic vaccine technology was published by Leiden University Medical Centre (LUMC) in the Journal for ImmunoTherapy for Cancer. It […]

November 8, 2022 - 2 minutesmins - By Liza Laws

News and Trends 8 Nov 2022

MedinCell’s partner AIC registers trial for drug for total knee replacement pain

A partner of MedinCell, Arthritis Innovation Corporation (AIC), has registered a phase 3 trial to look into an alternative drug to deal with pain after total knee replacement (TKR). Arthritis Innovation Corporation conducts and finances all development activities of the drug F14, or mdc-CWM, being trialed. It was registered with the safety and efficacy study […]

November 8, 2022 - 3 minutesmins - By Liza Laws

News and Trends 8 Nov 2022

AI program yields multiple novel RSV drug targets

Poolbeg Pharma says it has made a breakthrough in its Artificial Intelligence (AI) program with partner OneThree Biotech, Inc. through the discovery of novel drug targets for the treatment of respiratory syncytial virus (RSV). Following the completion of the build and optimization of a tailored AI model in June 2022, the OneThree team, using its […]

November 8, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 8 Nov 2022

Collaboration to develop CAR-T cell therapy for cutaneous T-cell lymphoma

The Peter MacCallum Cancer Centre (Peter Mac) and Cartherics Pty Ltd (Cartherics) have entered into a collaborative development program agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-001) for the treatment of cutaneous T-cell lymphoma (CTCL). “Patients with advanced stages of cutaneous T-cell lymphomas often have few treatment options left when their disease […]

November 8, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 8 Nov 2022

Study shows enhanced drug delivery to the brain

In a study recently published in the journal Nature Biomedical Engineering, Japanese researchers used a method called “lasso-grafting” to design therapeutics with enhanced longevity and brain penetration. Cell growth and repair are stimulated by biomolecules known as cytokines and growth factors. Unfortunately, delivering adequate concentrations of these molecules to the brain for treating neurological conditions […]

November 8, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 8 Nov 2022

BC Platforms receives $20M financing

Healthcare data management and analytics company BC Platforms (BCP) has closed a CHF 20 million ($20 million) financing round. The growth equity financing was led by new investor Jolt Capital (HQ Paris), a fully independent private equity firm that specializes in growth capital deeptech in Europe. The new financing will help accelerate the expansion of […]

November 8, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 8 Nov 2022

Telix Pharmaceuticals sees positive results in kidney cancer imaging study

Telix Pharmaceuticals Limited said it has highly positive top-line results from its pivotal phase III study of its investigational renal (kidney) cancer positron emission tomography (PET) imaging agent, TLX250-CDx (89 Zr- DFO-girentuximab). The ZIRCON study (Zirconium in Renal Cancer Oncology, NCT03849118) has met its co-primary and secondary endpoints. The study results delivered 86% sensitivity and […]

November 8, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 8 Nov 2022

Lipum starts chronic inflammatory disease drug study

Lipum AB (publ) says its phase 1 clinical study with the drug candidate SOL-116 has started and is progressing according to plan. A first dose group of eight healthy volunteers have received a dose, with two volunteers receiving placebo. Lipum’s drug candidate SOL-116 is a fully humanized antibody that is intended to address a major […]

November 8, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 8 Nov 2022

Rallybio announces positive phase 1 results for drug treating PNH and gMG

Affibody’s licensee Rallybio Corporation has announced positive topline results from a phase 1 single ascending dose (SAD) study in healthy participants of RLYB116. RLYB116 is a novel, potentially long-acting, subcutaneously administered inhibitor of complement factor 5, or C5, in development for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and generalized myasthenia gravis (gMG). […]

November 8, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 8 Nov 2022

Hormone discovery could predict long term health of men

Researchers have discovered the vital role of INSL3, a hormone that develops in men during puberty, which provides an early prediction of whether they could develop certain diseases in later life. Scientists from the University of Nottingham in the U.K. have discovered that the novel insulin-like peptide hormone, INSL3, is consistent over long periods of […]

November 8, 2022 - 3 minutesmins - By Jim Cornall

More News! 7 Nov 2022

Sensorion granted rare pediatric disease designation by FDA for lead therapy gene

Sensorion has announced that the US Food and Drug Administration (FDA) has granted rare pediatric disease designation to its lead therapy gene candidate, OTOF-GT. The gene therapy is intended for the treatment of otoferlin gene mediated hearing loss. Sensorion’s OTOF-GT gene therapy development program aims to restore hearing in people living with otoferlin deficiency, one […]

November 7, 2022 - 2 minutesmins - By Liza Laws

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Vir Biotech presents new data for functional cure of chronic Hep B virus

ISA Pharmaceuticals’ Amplivant adjuvant boosts immune response in SLP immunotherapy

MedinCell’s partner AIC registers trial for drug for total knee replacement pain

AI program yields multiple novel RSV drug targets

Collaboration to develop CAR-T cell therapy for cutaneous T-cell lymphoma

Study shows enhanced drug delivery to the brain

BC Platforms receives $20M financing

Telix Pharmaceuticals sees positive results in kidney cancer imaging study

Lipum starts chronic inflammatory disease drug study

Rallybio announces positive phase 1 results for drug treating PNH and gMG

Hormone discovery could predict long term health of men

Sensorion granted rare pediatric disease designation by FDA for lead therapy gene

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!